傲农生物(603363.SH)拟在高平市投建5000头母猪自繁自养养殖基地项目
格隆汇6月9日丨傲农生物(603363.SH)公布,为加快推进公司养殖产业发展,公司与高平市人民政府签署了投资合作协议书,公司拟在高平市投资建设5000头母猪自繁自养养殖基地项目,项目总投资预计为2亿元人民币。
项目名称:山西傲华5000头母猪自繁自养养殖基地项目。项目总投资2亿元(包含固定资产、生物资产及流动资金),建设规模为存栏5000头母猪场和30000头育肥场,项目建成后,预计年提供仔猪60000头与商品猪60000头。
该协议的签署对公司2020年度的经营业绩不构成重大影响。该协议的签署,符合公司的战略发展需要,有利于公司加快提升养殖规模,促进公司养殖产业的发展壮大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.